Responses
Treatments
Original article
Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis
Compose a Response to This Article
Other responses
No responses have been published for this article.